Published Dec 15, 2014
Rotterdam, The Netherlands – The current practice of prioritizing research in the context of conditional reimbursement can lead to wrong decisions since it relies on randomized controlled trials (RCT) based cost-effectiveness models, which do not reflect all uncertainties that are crucial in daily clinical practice. Treatment persistence, compliance, and broadening of indication can add substantial extra uncertainty to decisions about reimbursing treatments, according to a new study by the Institute for Medical Technology Assessment (iMTA) of Erasmus University Rotterdam. These uncertainties should be included in valuation-of-information analyses that are conducted to prioritize additional research, but usually they are not, as they are hardly relevant in RCTs. The additional ‘daily practice parameters’ do not merely add uncertainty, individually; they also interact with the RCT-based uncertainties, which may increase their impact. “Based on our experience with conditional reimbursement dossiers we know that decision-analytic models included in those dossiers do not properly represent daily practice. Thus, if the need for additional research is assessed at the beginning of the period of conditional reimbursement and this assessment is based solely on the RCT-based model, decisions can be very wrong.” said author Isaac Corro Ramos, PhD. Under the Dutch conditional reimbursement scheme, expensive new treatments can be accepted for reimbursement, provided that additional data is collected over a 4-year period in order to reduce uncertainty about the cost-effectiveness. Value-of-information analysis can be performed to decide which data is most relevant for increasing confidence in a correct reimbursement decision. The full study, “Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis,” is published in Value in Health

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now